Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2026)

Recursion Pharmaceuticals' Common Equity history runs 7 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Common Equity rose 9.72% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 9.72% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.29% from the prior year.
• Common Equity was $1.0 billion for Q1 2026 at Recursion Pharmaceuticals, down from $1.1 billion in the prior quarter.
• Across five years, Common Equity topped out at $1.1 billion in Q4 2025 and bottomed at $388.0 million in Q3 2022.
• A 5-year average of $659.2 million and a median of $493.6 million in 2022 frame the typical range for Common Equity.
• Peak annual rise in Common Equity reached 311.8% in 2022, while the deepest fall reached 35.22% in 2022.
• Recursion Pharmaceuticals' Common Equity stood at $485.8 million in 2022, then fell by 4.6% to $463.4 million in 2023, then surged by 123.28% to $1.0 billion in 2024, then rose by 9.29% to $1.1 billion in 2025, then decreased by 9.38% to $1.0 billion in 2026.
• Business Quant data shows RXRX's Common Equity at $1.0 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.